Linaclotide, Novel Therapy for the Treatment of Chronic Idiopathic Constipation and Constipation-Predominant Irritable Bowel Syndrome

被引：9

作者：

Vazquez-Roque, Maria I. ^{[1
]}

Bouras, Ernest P. ^{[1
]}

机构：

[1] Mayo Clin, Div Gastroenterol & Hepatol, Jacksonville, FL 32224 USA

来源：

ADVANCES IN THERAPY | 2013年 / 30卷 / 03期

关键词：

Constipation; Gastroenterology; Guanylate cyclase C; Guanylin; Irritable bowel syndrome; Linaclotide; Uroguanylin; GUANYLATE-CYCLASE-C; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; UNITED-STATES; GASTROINTESTINAL-TRACT; INTESTINAL SECRETION; ABDOMINAL-PAIN; TRANSIT; EFFICACY; MD-1100;

D O I：

10.1007/s12325-013-0012-9

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients. There is significant demand for more efficacious medications for the treatment of CC and IBS-C. Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C. It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen. In several clinical trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C. Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.

引用

页码：203 / 211

页数：9

共 34 条

[1] Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome [J].

Andresen, Viola ;

Camilleri, Michael ;

Busciglio, Irene A. ;

Grudell, April ;

Burton, Duane ;

Mckinzie, Sanna ;

Foxx-Orenstein, Amy ;

Kurtz, Caroline B. ;

Sharma, Vineeta ;

Johnston, Jeffrey M. ;

Currie, Mark G. ;

Zinsmeister, Alan R. .

GASTROENTEROLOGY, 2007, 133 (03) :761-768

[2] Health-related quality of life in young adults with symptoms of constipation continuing from childhood into adulthood [J].

Bongers, Marloes E. J. ;

Benninga, Marc A. ;

Maurice-Stam, Heleen ;

Grootenhuis, Martha A. .

HEALTH AND QUALITY OF LIFE OUTCOMES, 2009, 7

[3]

Brady S, 2005, MICROBIA SUCCESFULLY

[4]

Bryant AP, 2006, GASTROENTEROLOGY, V130, pA598

[5] Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract [J].

Bryant, Alexander P. ;

Busby, Robert W. ;

Bartolini, Wilmin P. ;

Cordero, Etchell A. ;

Hannig, Gerhard ;

Kessler, Marco M. ;

Pierce, Christine M. ;

Solinga, Robert M. ;

Tobin, Jenny V. ;

Mahajan-Miklos, Shalina ;

Cohen, Mitchell B. ;

Kurtz, Caroline B. ;

Currie, Mark G. .

LIFE SCIENCES, 2010, 86 (19-20) :760-765

[6]

Bryant AP, 2005, GASTROENTEROLOGY, V128, pA464

[7] Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit [J].

Busby, Robert W. ;

Bryant, Alexander P. ;

Bartolini, Wilmin P. ;

Cordero, Etchell A. ;

Hannig, Gerhard ;

Kessler, Marco M. ;

Mahajan-Miklos, Shalina ;

Pierce, Christine M. ;

Solinga, Robert M. ;

Sun, Li Jing ;

Tobin, Jenny V. ;

Kurtz, Caroline B. ;

Currie, Mark G. .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 649 (1-3) :328-335

[8]

Busby RW, 2005, GASTROENTEROLOGY, V128, pA464

[9] A placebo-controlled trial of prucalopride for severe chronic constipation [J].

Camilleri, Michael ;

Kerstens, Rene ;

Rykx, An ;

Vandeplassche, Lieve .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (22) :2344-2354

[10]

Castro J, 2012, GASTROENTEROLOGY, V142, pS699

← 1 2 3 4 →